Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Acura Pharmaceuticals Is Grossly Undervalued And Poised For Rapid Growth
StockPro2X • ACUR • Fri, May 17, 11:04 ET
Antares: Reiteration Of My Buy Recommendation
Smith On Stocks • PFE, TEVA, ATRS • Thu, May 16, 14:01 ET
Contraceptive Ring: Another Under-The-Radar Catalyst For Antares
Ali Yasar • ATRS • Wed, May 15, 06:37 ET
Valeant Pharmaceuticals: Don't Take Profits Yet, Still Room To Grow In 2013
Jeffrey To • VRX • Fri, May 10, 13:47 ET
InSite Vision: An Over-looked Company With 2 Interesting Drug Candidates And An Upcoming Catalyst
Smith On Stocks • INSV.OB • Fri, May 10, 12:03 ET
Thrift Shopping At Hospira
Christopher Pavese • HSP • Tue, May 7, 12:12 ET
The ODAC Postmortem: Lessons Learned Part 2, Delcath Systems
PropThink • DCTH • Mon, May 6, 09:41 ET
Antares: Challenger Emerging Against 400-Year Old Condom
Ali Yasar • ATRS • Thu, May 2, 09:29 ET
Delcath Systems: Too Many Red Flags To Hold Through May 2nd ODAC
Linch Financial • DCTH • Mon, Apr 29, 21:11 ET
Seizing The Blockbuster Opportunity Buried In Conservative Modeling At Antares Pharma
Ali Yasar • ATRS • Thu, Apr 25, 13:40 ET
Delcath: A Cancer Treatment Biotech With Good Short And Long-Term Potential
Healthcare Specialist • DCTH • Sun, Apr 21, 03:11 ET
Society And The FDA Are Ready For Acura, Are You?
Craig Keolanui • JNJ, PFE, ACUR • Fri, Apr 19, 19:42 ET
PetMed Express: This Stock Is No Dog
Henry Kawabe • AMZN, TGT, WMT • Thu, Apr 18, 08:08 ET
FDA Upgrades Acura Pharmaceuticals To A Public Health Priority
Natty Greene • PFE, ACUR • Wed, Apr 17, 06:31 ET
Alkermes Still Not Getting Full Credit For Its Pipeline
Stephen Simpson • ACOR, AZN, JNJ • Fri, Apr 5, 12:00 ET
2 Strategic Partnerships Fueling The Performance Of Acura Pharmaceuticals
Heather Ingrassia • ACUR • Fri, Apr 5, 08:12 ET
InSite Vision Concludes Royalty Deal On Besivance That Extends Cash Runway
Smith On Stocks • INSV.OB, SWKH.OB • Tue, Apr 2, 12:36 ET
A Deep Dive Into Antares Pharma's Buyout Thesis
Ali Yasar • PFE, ATRS • Tue, Mar 26, 16:02 ET
Valeant Pharma Doing Good Job Fitting Its Pieces Together
Robert Freedland • VRX • Mon, Mar 25, 01:47 ET
Valeant Pharmaceuticals - Investors Send Shares To All Time Highs After Yet Another Acquisition
The Value Investor • OMPI, VRX • Fri, Mar 22, 08:29 ET
Flamel: Near-Term, Under The Radar FDA Catalyst Trade
Mike Havrilla • GSK, FLML • Thu, Mar 21, 16:51 ET
Antares: A Compelling Long-Term Investment
Alexander Maxwell • BPAX, PFE, ATRS • Thu, Mar 21, 12:14 ET
Alkermes: R&D Complementing Royalties
Stock Traders Daily • ALKS • Thu, Mar 21, 02:19 ET
InSite Vision: Positive Phase III Trial Results For BromSite Reduces Much Of Downside Risk In The Stock
Smith On Stocks • INSV.OB • Tue, Mar 19, 09:55 ET
Delcath Poised For Run-Up Into FDA Advisory Panel Meeting
Mike Havrilla • DCTH • Sun, Mar 17, 17:45 ET
Delcath Drifts 30% Higher On PDUFA Anticipation
Brian L. Wilson • DCTH • Mon, Mar 11, 05:27 ET
Delcath Systems: Bullish On Melblez FDA Panel Vote And Subsequent Approval
PropThink • VVUS, DCTH • Fri, Mar 8, 10:56 ET
Delcath Systems: 'Improving The Bicycle' In Chemotherapy
Linch Financial • DCTH • Wed, Feb 27, 12:59 ET
The Street Is Much Too Optimistic About Hospira
Stephen Simpson • BAX, CFN, NVS • Thu, Feb 14, 15:46 ET
Post-Tysabri, Will Elan Waste The Windfall?
Stephen Simpson • BIIB, FRX, SPPI • Fri, Feb 8, 10:14 ET
Generex: Research For Sale On The Cheap
Thomas Barnard • NVO, LLY, GNBT.OB • Thu, Jan 31, 03:16 ET
3 Reasons Delcath Systems Appears Undervalued
Justin Kuepper • CLSN, DNDN, THLD • Wed, Jan 23, 18:36 ET
InSite Vision: Upcoming Results On The DOUBle Trial May Not Be As Binary As I Have Been Thinking
Smith On Stocks • INSV.OB • Wed, Jan 23, 17:47 ET
Savvy Investors Discover Antares' Growing Revenue Stream
James Stocklasar Thomas Jr. • ATRS • Thu, Jan 17, 03:31 ET
Antares Rallies Quickly And Confidently On Newest Developments
Brian L. Wilson • ATRS • Fri, Jan 11, 08:27 ET
Why Is Antares Rising So Quickly?
James Stocklasar Thomas Jr. • ATRS • Wed, Jan 9, 12:47 ET
Valeant Pharmaceuticals International, Inc.: Solid Growth Pick
Zacks Investment Research • VRX • Tue, Jan 8, 04:26 ET
Why Growth Stock Antares Is Moving Higher
James Stocklasar Thomas Jr. • ATRS • Mon, Jan 7, 14:32 ET
Columbia Laboratories Inc.: Recent Events Lead To An Opportune Entry Point
JDBloomington • ACT, CBRX • Fri, Dec 21, 2012, 12:30 ET
InSite Vision: A Small Niche With No Competitors Point To High Upside Potential
Richard Richter • INSV.OB • Thu, Dec 20, 2012, 05:52 ET
InSite Vision: Upcoming Topline Results From Clinical Trials Present A Buying Opportunity
Smith On Stocks • INSV.OB • Tue, Dec 18, 2012, 17:14 ET
Positive Year End Catalysts Make Acura A Buy
Natty Greene • PFE, ACUR • Mon, Dec 10, 2012, 05:26 ET
Unlocking Antares' Vision For Arthritis Patients
Shadow Play • ATRS • Fri, Dec 7, 2012, 18:31 ET
How Steve Cohen Moves Stock
Felix Salmon • ELN • Tue, Nov 27, 2012, 05:27 ET
Why Antares Pharma Will Be A Powerhouse In The Future
Shadow Play • ATRS • Wed, Nov 14, 2012, 03:29 ET
Valeant: Top Hedge Fund Managers Like This Medical Stock
FAF Research • AGN, GSK, JNJ • Thu, Nov 8, 2012, 15:38 ET
3 Dirt Cheap Drug Companies About To Make A Comeback
Louis Dematteis • IPCI, PSDV, INSV.OB • Tue, Nov 6, 2012, 03:16 ET
Delcath Systems: A Frustrating Stock With Quite A Bit Of Value Potential
Brian L. Wilson • DCTH • Wed, Oct 17, 2012, 18:54 ET
Dilution Is The Solution To Pollution
Eric Wick • PSTI, ATRS • Tue, Oct 9, 2012, 12:24 ET
Taking Note Of IntelliPharmaCeutics' Now Imminent FDA Decision
M. E. Garza • IPCI • Mon, Oct 8, 2012, 06:53 ET

First Page
Previous Page
1 - 50 of 253
Next Page
Last Page